A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study
Latest Information Update: 26 Aug 2022
At a glance
- Drugs MVC COV1901 (Primary) ; Aluminum hydroxide; CpG; Protein S
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medigen Vaccine Biologics
- 23 Aug 2022 Status changed from active, no longer recruiting to completed.
- 13 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
- 27 Jan 2022 Planned End Date changed from 1 Mar 2022 to 1 May 2022.